

Application ID:	
CIA Surname:	

Additional Questions

Priority-driven Young Investigator Project Grants: Category F funding

APPLICATION FOR YOUNG INVESTIGATOR PRIORITY-DRIVEN COLLABORATIVE CANCER RESEARCH SCHEME GRANTS COMMENCING 2010

- This Additional Questions form is to be completed by young investigators seeking to apply for Category F funding from Cure Cancer Australia Foundation.
- To be submitted to Cancer Australia as a separate PDF file from your NHMRC Detailed Background and Research Plan PDF file.
- The file name must be: '[App ID]_CancerAustralia_AddQs_[CIA Family Name].pdf' eg '123456_CancerAustralia_AddQs_Smith.pdf'

Please submit Additional Questions to grants@canceraustralia.gov.au

- Please insert your NHMRC application ID and CIA surname in the header
- For Yes / No answers, please place an X to the left of the preferred option(s)
- Insert additional rows as required

The **Additional Questions** are compulsory. A written response addressing each *Additional Question* must be provided. Any application that does not respond to an *Additional Question* or indicates that a question is 'not applicable' / 'not relevant' (or equivalent) will be **deemed ineligible** for funding through the Priority-driven Collaborative Cancer Research Scheme and will not be reviewed by Cancer Australia and/or its funding partners.

The *Additional Questions* will be **assessed independently** of the rest of the grant application (including the *Detailed Background and Research Plan* and the *Cancer Council Supplementary Questions*). Responses to the *Additional Questions* should be written so they can be **read without reference to the *Detailed Background or Research Plan*** as reviewers may not have access to these documents when assessing the *Additional Questions*.

Responses to *Additional Questions* must be provided in text boxes provided. Response must be in **Ariel 10 point font**.

1. Chief Investigator A - details

Application ID			
Name			
Institution			
Institution		State	

Application ID:	
CIA Surname:	

Address			
Telephone No		Email	

Note the CIA is responsible for managing the collaboration and reporting to Cancer Australia

2. Eligibility

Provide the date of the letter advising you that your PhD or equivalent qualification was approved.
(Note: you must be ≤ 7 years post-doctoral on the closing date for applications in order to be eligible.)

...../...../..... (DD/MM/YYYY)

3. Exceptional Circumstance

If required, outline any exceptional circumstances relating to your eligibility (e.g., maternity leave or sick leave subsequent to obtaining doctoral qualification; periods of teaching or clinical practice are not regarded as exceptional circumstances (limit 2000 characters).

4. Administering Institution - details

Please include name and department address of Research Admin Officer (RAO)

Name of RAO						
Department						
Institution						
Address						
Suburb		State		Postcode		
Telephone no.		Email				

Application ID:	
CIA Surname:	

5. Scientific Title and plain English description of your project

Please ensure:

- the Scientific Title of your project is the same title as used on your NHMRC application form.
- the plain English description of your project does not exceed 4-5 lines. You may utilise the short plain English description provided to the NHMRC to answer this question.

Type your answer here

Application ID:	
CIA Surname:	

6. Please provide a one page synopsis of your research project.

(you may insert text from your NHMRC synopsis) Page limit: 1 page

Application ID:	
CIA Surname:	

7. Which research priority area/s does your grant application relate to?

- Place an X to the left of all research priority areas that are **relevant** and directly relate to your grant application.

Cancer Australia and Cure Cancer Australia Foundation will consider co-funding successful grant applications. Applicants are encouraged to review the list of research priority areas and to select all research priority areas that **DIRECTLY** relate to the proposed research project.

When applying for funding offered through Category F funding, applicants **MUST** ensure that their research project:

- Aligns with the research priority area/s of Cure Cancer Australia Foundation; and
- Can be conducted within the duration and the funding amount offered by Cure Cancer Australia Foundation (see below).

F. FUNDING OF UP TO 1 YEAR DURATION AND UP TO \$90,000 (GST-EX):

Cancer Australia: Research priority areas

Improving outcomes through:

- | | |
|--|---|
| | <ul style="list-style-type: none"> Prevention of cancer |
| | <ul style="list-style-type: none"> Improving screening programs |
| | <ul style="list-style-type: none"> Early detection of cancer |
| | <ul style="list-style-type: none"> The application of emerging new treatments and/ or technologies |
| | <ul style="list-style-type: none"> Coordination, integration or delivery of treatment and care using a multidisciplinary approach. |

Cancer Australia's research priorities aim to reduce the burden of cancer on all Australians.

Research undertaken should have a specific emphasis on populations with poorer cancer outcomes, such as Aboriginal and Torres Strait Islander peoples and particular consideration will be given to health service and health economic research, and the translation or implementation of research.

Given their burden of disease and mortality across the community, research addressing cancers of the colon and rectum, lung, pancreas, stomach, cancer of unknown primary, and lymphoma are strongly encouraged.

Cancer Australia: Boost Cancer Research

- | | |
|--|--|
| | <ul style="list-style-type: none"> Trials-based research in cancer prevention/screening* |
| | <ul style="list-style-type: none"> Trials-based research in treatment, psychosocial care, supportive care, and/ or palliative care* |

* Trials must be industry-independent cancer clinical trials. Industry-independent clinical trials are defined as investigator-initiated clinical trials where collection, analysis and ownership of data together with dissemination of findings lie within the control of the research collaborative. International collaborative trials are strongly encouraged.

Cancer Australia: National Lung Cancer Program

Application ID:	
CIA Surname:	

<ul style="list-style-type: none"> Research towards identifying barriers to timely and appropriate initial diagnosis and referral of people with suspected or diagnosed with lung cancer. <p>Research supported would include primary care research.</p> <p>Research with a specific emphasis on Aboriginal and Torres Strait Islander peoples, people from regional, rural and remote locations, and people from cultural and linguistically diverse backgrounds is strongly encouraged.</p>
<ul style="list-style-type: none"> Research towards demonstrating the clinical utility of potential biomarkers for lung cancer in a prospective validation collaborative multi-site study.

Cancer Australia: Radiation Oncology	
<ul style="list-style-type: none"> Clinical research in radiation oncology with a particular focus on health outcomes and cost effectiveness 	
<ul style="list-style-type: none"> Optimal use of workforce including role definitions and clinical practice guidelines 	
<ul style="list-style-type: none"> Defining and improving service delivery, communication and pathways for patient access to radiation therapy 	
<ul style="list-style-type: none"> Evaluation of new treatments and technologies such as the role of IMRT and IGRT in treatment and the role of PET in biologically characterising treatment, response and subsequent prognosis 	

Cure Cancer Australia Foundation	
---	--

<ul style="list-style-type: none"> Project grants in any field of research (including clinical) into malignant disease, that will provide “start up” funding to support post-doctoral researchers with less than 7 years post-doctoral experience at the time of application. <p>This funding cannot be used to provide a salary or other support for a young investigator as part of a larger PdCCRS project grant application</p>
--

Cure Cancer Australia Foundation wishes to fund innovative, high-achieving, early-career researchers, and will be assessing the Track Record and Publications of the Chief Investigator submitted as part of the NHMRC application process to determine priority for these grants.

If applying for funding by the Cure Cancer Australia Foundation, please also provide year and month of award of doctorate or equivalent qualification

Year		Month	
-------------	--	--------------	--

<p>8. Research in identified priority area/s</p> <ul style="list-style-type: none"> List the applicable priority area/s selected in question 5 (above) Justify how your research directly relates to each of these selected priority areas (½-1 page maximum). <p>Please note: if your research project does not clearly align with the selected research priority areas, the funding partner is under no obligation to consider your project for funding</p> <p>Your response to this question will determine your eligibility for funding by Cancer Australia and/or its funding partners.</p>

Application ID:	
CIA Surname:	

Research priority area: <i>(insert priority)</i>
Funding partner:
Discuss alignment of your project with the priority area:
Research priority area: <i>(insert priority)</i>
Funding partner:
Discuss alignment of your project with the priority area:

Add more rows as required to address each selected priority area.

Application ID:	
CIA Surname:	

9. Specific criteria

Explain how your proposal addresses each of the following criteria:

A. Track record of the applicant in regard to opportunity

A1: List of publications

Please list all publications (refereed journal articles and book chapters, in ascending chronological order [most recent last]) (no limit on number of characters)

Application ID:	
CIA Surname:	

A2. Please describe the applicants role in key publications and patents (limit 1000 characters)

A3. Research experience

- Please provide details of previous research experience highlighting the most significant contributions, evidence of novel approaches, and those most relevant to the proposed research. (limit 2,000 characters)

A4. Other relevant experience

- Provide details of clinical training and practice relevant to cancer if any (and whether your involvement in clinical practice will impact on your ability to carry out the proposed project), details of postgraduate teaching if any (indicating whether you are/were the sole or co-supervisor, and whether any of your students have completed their degrees), and details of any administrative responsibilities (including laboratory, departmental, institutional, or external). (limit 2,000 characters)

A5. Academic Qualifications/ Awards

- Please enter up to 20 of your academic qualifications/awards, starting with the most recent. Indicate date, and where obtained.

Please note that while there is no limit on number of characters, there is a limit on the number of items that can be included - if this limit is ignored, the panel will only take the first 20 items into account

Application ID:	
CIA Surname:	

B. How the research will contribute to the career development of the applicant
B1. Career Development Objectives
<ul style="list-style-type: none"> Briefly outline your career development objectives for the next five years and how the proposed project will foster these. If relevant, describe any collaborations that will be facilitated by the project. (limit 1,000 characters)
B2. Research Environment
<ul style="list-style-type: none"> Describe your reasons for choosing the laboratory or place where you plan to work, including mentoring arrangements. (limit 1000 characters)
C. Relevance to cancer Control
<ul style="list-style-type: none"> Describe how your proposed research is relevant to cancer control. Please use lay terms that would be suitable for a press release. (limit 1000 characters)
D. Involvement of consumer representatives
<ul style="list-style-type: none"> Please indicate whether consumers have been consulted about the relevance of the study or its design. Outline how consumer involvement could be included usefully in the development of this project (limit 1000 characters)
<p><i>Please refer to the “Guide for Applying for Grants from the Priority-driven Collaborative Cancer Research Scheme” for additional guidance.</i></p>

Application ID:	
CIA Surname:	

GRANT APPLICATIONS SUBMITTED TO CANCER AUSTRALIA AND/OR NHMRC AND/OR CANCER COUNCIL AND/OR HEART FOUNDATION

10. Have you submitted this grant application to Cancer Australia and its partners and/or to the NHMRC and/or Cancer Council and/or Heart Foundation?

	No This application has been submitted for consideration to Cancer Australia and/ or Cure Cancer Australia Foundation only
	Yes This Grant application has been submitted for consideration of funding to both Cancer Australia/ Cure Cancer Australia Foundation and other funders including the NHMRC and/or Cancer Councils and/or Heart Foundation.

- Applicants **cannot** receive funding from both Cancer Australia/ Cure Cancer Australia Foundation and the NHMRC/Cancer Councils/Heart Foundation for the same research project.
- The NHMRC and Cancer Australia will work together to identify which grant applications applying to both organisations will be funded by the NHMRC or Cancer Australia and will ensure that no applicant will have to choose between grant funding from the NHMRC and Cancer Australia and Cure Cancer Australia Foundation.
- Under s 136.1 of the Commonwealth Criminal Code, it is an offence to provide false or misleading information to a Commonwealth body in an application for a benefit, punishable by up to 12 months imprisonment. In addition, if an application contains information that is false or misleading, it may be excluded from any further consideration for funding. The Commonwealth Government is committed to protecting its revenue, expenditure and property

Application ID:	
CIA Surname:	

from any attempt, either by members of the public, contractors, sub-contractors, agents, intermediaries or its own employees to gain financial or other benefits by deceit.

- If the NHMRC/ Cancer Australia believes that omissions or inclusion of misleading information are intentional, it will refer the matter for appropriate legal action.

11. Budget

F. FUNDING OF UP TO 1 YEAR DURATION AND UP TO \$90,000 (GST-EX)

- The total budget provided by the Cure Cancer Australia Foundation for post-doctoral researchers with less than 7 years post-doctoral or since graduation from medical school cannot exceed a budget of \$90,000 (GST exclusive) and is limited to one year. This funding category cannot be used to provide a salary or other support for a young investigator as part of a larger PdCCRS project grant application.
- Cure Cancer Australia Foundation wishes to fund innovative, high-achieving, early-career researchers, and will be assessing the Track Record and Publications of the Chief Investigator submitted as part of the NHMRC application process to determine priority for these grants.
- Applications that exceed this amount will not be considered eligible for funding by Cure Cancer Australia Foundation.

Cure Cancer Australia Foundation	Year 1	Total

12. Additional funding opportunities

If your application is unsuccessful, do you provide permission for Cancer Australia to pass on your application (in confidence) to other research funders for consideration of funding?

<input type="checkbox"/>	Yes
<input type="checkbox"/>	No

13. Agreements

Please indicate your agreement to comply with the following conditions by selecting Yes or No. Failure to comply may impact on your eligibility to receive funding through the Priority-driven Collaborative Cancer Research Scheme.

Yes/No	By submitting this application, the Administering Institution is willing to comply with the terms and conditions outlined in the Cancer Australia funding agreement (http://www.canceraustralia.gov.au/research-and-clinical-trials/priority-driven-research.aspx).
Yes/No	I agree to use the funds to undertake activities as outlined in this research proposal and not for activities that do not relate directly to this application, without prior approval from Cancer Australia.

Application ID:	
CIA Surname:	

Yes/No	<p>I acknowledge that I am ineligible for funding, or funding may be terminated, if I am:</p> <ul style="list-style-type: none"> • an applicant for, or in receipt of funds from, the tobacco industry or organisations deemed by Cancer Australia to be associated with the tobacco industry, regardless of whether the funds are received directly, through collaborators or by other means. The Smoking and Health Research Foundation of Australia is deemed to be associated with the tobacco industry; • employed in a research institute or organisation or, in the case of universities, Faculty or School that allows applications or receives funds from the tobacco industry, whatever the use of those funds may be; or • employed in a University that accepts funds from the tobacco industry for health related research or services, wherever in the University that research may be done or those services supported.
<p>Please note: That if your application is successful, your name, the title of my project and amount of funding may appear on the websites and may be used in media releases and other reports/publications by Cancer Australia and its funding partners.</p>	

COMMON SCIENTIFIC OUTLINE

The Common Scientific Outlines in Question 11 are the result of collaborative effort between the NCI in the US, the NCRI in the UK, and their partners. It is a classification system organised around seven broad areas of scientific interest in cancer research, plus subgroups. Click on the following link to view category descriptions in full <http://www.cancerportfolio.org/cso.jsp>

14. Which categories of research best describe your grant application? Place an 'x' against all that are applicable, and also indicate with * the category which best describes the research focus of your project.

Biology

	1.1 Normal functioning
	1.2 Cancer initiation: Alterations in chromosomes
	1.3 Cancer initiation: Oncogenes and tumour suppressor genes
	1.4 Cancer progression and metastasis
	1.5 Resources and infrastructure
	1.6 Cancer related biology

Aetiology

	2.1 Exogenous factors in the origin and cause of cancer
	2.2 Endogenous factors in the origin and cause of cancer
	2.3 Interactions of genes and/or genetic polymorphisms with exogenous and/or endogenous factors
	2.4 Resources and infrastructure related to aetiology

Application ID:	
CIA Surname:	

Prevention

	3.1 Interventions to prevent cancer: Personal behaviours that affect cancer risk
	3.2 Nutritional science in cancer prevention
	3.3 Chemoprevention
	3.4 Vaccines
	3.5 Complementary and alternative prevention approaches
	3.6 Resources and infrastructure related to prevention

Early Detection, Diagnosis, and Prognosis

	4.1 Technology development and/or marker discovery
	4.2 Technology and/or marker evaluation with respect to fundamental parameters of method
	4.3 Technology and/or marker testing in a clinical setting
	4.4 Resources and infrastructure related to detection, diagnosis, or prognosis

Treatment

	5.1 Localised therapies - Discovery and development
	5.2 Localised therapies - Clinical
	5.3 Systemic therapies - Discovery and development
	5.4 Systemic therapies - Clinical applications
	5.5 Combinations of localised and systemic therapies
	5.6 Complementary and alternative treatment approaches
	5.7 Resources and infrastructure related to treatment

Cancer Control, Survivorship, and Outcomes Research

	6.1 Patient care and survivorship issues
	6.2 Surveillance
	6.3 Behaviour related to cancer control
	6.4 Cost analyses and healthcare delivery
	6.5 Education and communication
	6.6 End-of-Life care
	6.7 Ethics and confidentiality in cancer research
	6.8 Complementary and alternative approaches for supportive care of patients and survivors
	6.9 Resources and infrastructure related to cancer control, survivorship, and outcomes research

Scientific Model Systems

Application ID:	
CIA Surname:	

	7.1 Development and characterisation of model systems
	7.2 Application of model systems
	7.3 Resources and infrastructure related to scientific model systems